Search Results

Endovascular Engineering’s Helo Thrombectomy System for PE Studied in ENGULF

November 7, 2023—Endovascular Engineering, Inc. (E2) announced recently that initial results from its ENGULF study demonstrated successful outcomes among the first 15 patients evaluated in the trial using E2’s Helo thrombectomy system for the treatment of acute submassive pulmonary embolism (PE).

Endovascular Engineering’s Helo Thrombectomy System Receives IDE Approval for ENGULF Pivotal Trial to Treat PE

January 11, 2024—Endovascular Engineering (E2), a developer of clot removal technologies for venous thromboembolism, announced FDA approval for an investigational device exemption (IDE) for the ENGULF United States pivotal trial.

Study Uses PERT Consortium Registry Data to Examine Practice Patterns and Outcomes in High-Risk Pulmonary Embolism

January 17, 2024—In a retrospective analysis using data from the PERT Consortium registry, Kobayashi et al found high rates of in-hospital mortality and major bleeding in patients with high-risk pulmonary embolism (PE) as compared with intermediate-risk PE.